Archives
-
Bestatin and Actinonin: Evidence for Intracellular Action
2026-10-08
Grujic and Renko compared the antiproliferative effects of bestatin and actinonin with cell-surface aminopeptidase inhibition in U937 and K562 cells. Their transporter-modifier experiments support a predominantly intracellular mechanism and show why verapamil-associated changes in drug sensitivity should not automatically be interpreted as evidence for calcium-signaling effects.
-
IMP and APEX-RNA-MS: Evidence Guide
2026-10-08
IMP is listed as SKU M1405, but the supplied dossier does not establish its chemical identity or mechanism. APEX-RNA-MS is a separate research strategy that profiles spatially proximal RNA modifications by combining proximity labeling with nucleoside LC-MS analysis.
-
Angiotensin II: From Vascular Signal to RAS Context
2026-10-07
Angiotensin II is more than a potent vasopressor: it is a context-dependent RAS signal linking receptor pharmacology, vascular remodeling, and ACE2 biology. This evidence-focused guide explains what current findings support, what remains uncertain, and how A1042 can be interpreted in research.
-
Ertugliflozin: Renal Transport to Brain Signaling
2026-10-07
Ertugliflozin (PF-04971729) is best known for glucose reabsorption inhibition, but emerging evidence links it to brain insulin signaling and tau biology. This article evaluates that kidney-to-brain hypothesis, explains the key rat-model findings, and defines the boundaries of current Alzheimer’s disease evidence.
-
UTP Solution and TRIM66: Five Evidence Questions
2026-10-06
A source-grounded overview of UTP biology, the TRIM66 olfactory-receptor study, evidence strength, interpretation, and the boundaries of what can reasonably be concluded.
-
2'-O-Methyladenosine: From Signal to Meaning
2026-10-06
2'-O-Methyladenosine is more than a modified nucleoside signal: it is a useful lens for separating analytical detection from biological interpretation. This article examines its RNA biology, purine metabolism context, research applications, and the evidence limits surrounding current UHPLC–MS/MS findings.
-
8-Oxo-GTP in Cell-Free Translation Research
2026-10-05
8-Oxo-GTP provides a useful lens for examining how altered guanine nucleotides may be interpreted in defined biochemical systems. This article connects that question to a 2025 study demonstrating continuous in situ synthesis of all 21 translation-relevant tRNAs in a recombinant PURE system, while clearly separating direct evidence from broader interpretation.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-10-05
The reference study identifies Kupffer cell-expressed TMEM16F as a central determinant of liver protection during Listeria monocytogenes infection. Its findings connect plasma-membrane repair and lipid scrambling with restrained inflammation, preserved hepatic metabolism, and reduced infection-associated tissue injury.
-
AAPH in Oxidative Stress Research: Evidence and Limits
2026-10-04
AAPH, or 2,2'-Azobis(2-methylpropionamidine) dihydrochloride, is used conceptually as a water-soluble source of peroxyl-radical stress in biochemical and cellular research. Evidence from a 2024 hazelnut-protein study shows that AAPH-associated oxidation can alter solubility, interfacial properties, and gel structure, but the findings are model-specific and should not be treated as direct evidence of cellular, clinical, or food-storage outcomes.
-
APEX-RNA-MS Maps RNA Modifications in Cell Structures
2026-10-03
Seo, Dhingani, and Kleiner introduce APEX-RNA-MS, a proximity-labeling and nucleoside LC-MS strategy for measuring RNA modification patterns near defined protein neighborhoods. Applied to stress granules, P-bodies, and DNA damage foci, the study reports enrichment of m6A and m5C at DNA damage sites and identifies modified tRNA populations associated with stress granules.
-
NU7441 (KU-57788) DNA-PK Workflow Guide
2026-10-02
NU7441 (KU-57788) combines high DNA-PK selectivity with practical utility in DNA repair research, oncology research, and cell-cycle studies. This guide translates its biochemical profile and a brain pericyte HIV-1 study into assay-ready workflows, controls, and troubleshooting decisions.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-10-01
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for local treatment of bladder cancer. In cell and orthotopic mouse models, intravesical p21-LNP delivery restored nuclear p21, suppressed tumor growth, altered cell-cycle signaling, and limited systemic exposure, while remaining an experimental strategy rather than a clinical therapy.
-
Dabigatran Etexilate: Oral Direct Thrombin Inhibition
2026-10-01
This clinical review evaluates dabigatran etexilate as the first marketed oral direct thrombin inhibitor, emphasizing its prodrug activation, predictable anticoagulant effects, and independence from cytochrome P450 metabolism. Its findings explain why dabigatran offered a practical alternative to vitamin K antagonists while also identifying renal function, bleeding, and indication-specific evidence as important constraints.
-
AAPH: Controlled Oxidative Stress Inducer
2026-09-30
AAPH, also called 2,2'-Azobis(2-methylpropionamidine) dihydrochloride, is a water-soluble reactive oxygen species generator for reproducible in vitro oxidative damage models. Its thermal radical chemistry supports erythrocyte hemolysis, lipid peroxidation, protein oxidation, and antioxidant activity evaluation.
-
Nicotine Signaling in Chronic Kidney Disease
2026-09-30
Jain and Jaimes synthesize clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and profibrotic signaling. The review’s main practical value is its mechanism-based framework for separating nicotine effects from the broader toxicity of cigarette smoke and for designing better renal injury studies.